Stocktoria

Monte Rosa Therapeutics, Inc. GLUE

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-06-24

Monte Rosa Therapeutics, Inc. statistics & valuation

Market cap$1.9B
P / S15.2×
P / B8.1×
Net margin-31.2%
Return on equity-16.6%
FCF margin-22.2%
Return on capital-14.1%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Net margin (%)
-96.10% -31.20% 202020212022202320242025
Gross margin (%)
202020212022202320242025
Operating margin (%)
-107.30% -43.80% 202020212022202320242025
Return on equity (%)
-21.30% -40.00% -75.50% -32.60% -16.60% 202020212022202320242025
Shares outstanding
1.7M 46.5M 49.3M 51.4M 73.9M 83.1M 202020212022202320242025
Net debt ($)
202020212022202320242025
Share buybacks ($)
202020212022202320242025
Return on assets (%)
-72.70% -20.20% -31.70% -44.60% -16.60% -8.60% 202020212022202320242025
Free cash flow margin (%)
50.30% -22.20% 202020212022202320242025
Debt / equity (×)
202020212022202320242025
EPS ($)
202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020
Operating margin-43.8%-107.3%————
Net margin-31.2%-96.1%————
FCF margin-22.2%50.3%————
Return on assets-8.6%-16.6%-44.6%-31.7%-20.2%-72.7%
Return on equity-16.6%-32.6%-75.5%-40.0%-21.3%73.6%
Current ratio6.122.405.0710.7920.961.49

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.